Clinical Trails

A Phase 1 study found that the new radioligand therapy [177Lu]Lu-D-Dan-Phe-PSMA is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC). The treatment was designed to stay in the body and tumors longer than current therapies such as Pluvicto, allowing it to deliver more radiation directly to cancer cells. In the highest dose […]

MimiVax Inc. and Roswell Park Comprehensive Cancer Center have started a Phase 2 clinical trial to test the cancer vaccine SurVaxM in patients with worsening neuroendocrine tumors (NETs). The study will compare SurVaxM plus the chemotherapy drug temozolomide with temozolomide alone. SurVaxM is designed to help the immune system attack survivin, a protein linked to

Updated Phase 2 trial results showed that combining rintatolimod with Pembrolizumab and cisplatin may greatly improve outcomes for patients with platinum-sensitive recurrent ovarian cancer. Among 24 evaluable patients, the treatment achieved a 50% objective response rate, including 5 complete responses. This was much higher than the response rate previously seen with pembrolizumab alone. The clinical benefit

Updated interim results from the Phase 2 LEGEND trial show that detalimogene voraplasmid may be an effective treatment for patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). The therapy is delivered directly into the bladder to trigger a local immune response against tumors. The study showed that 54% of patients achieved a complete response

A Phase 1b study evaluated the immunotherapy simlukafusp alfa in patients with metastatic renal cell carcinoma. The drug was tested in combination with atezolizumab, with or without bevacizumab. While the treatment showed biological activity, it did not improve outcomes compared to current standard therapies. The triplet combination showed higher response rates than the doublet. The

Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, added to standard FOLFIRI and bevacizumab may significantly improve outcomes in RAS-mutant, microsatellite-stable metastatic colorectal cancer. The combination performed much better than historical results for second-line treatment. Median duration of response reached 19.5 months compared with about 4 to

The Phase 2 CAR-PRISM trial shows striking results for high-risk smoldering multiple myeloma using the CAR T-cell therapy ciltacabtagene autoleucel (Carvykti). A single infusion led to 100% of patients achieving minimal residual disease (MRD) negativity at a very deep level. At a median follow-up of 15.3 months, all patients achieved complete or stringent complete responses, with

Early clinical data suggest that ozekibart (INBRX-109), a DR5 agonist, could offer a new treatment option for Ewing sarcoma, a rare and aggressive cancer. In a Phase 1 study, ozekibart was combined with standard chemotherapy (temozolomide and irinotecan) in patients with relapsed or refractory disease. Among 31 patients, the response rate reached 64.5%, much higher

The Phase 2 PRIMO trial found that duvelisib (Copiktra), an oral drug targeting PI3K-δ and PI3K-γ, can work as a single treatment for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In the study of 123 heavily pretreated patients, nearly half responded to the drug. The overall response rate was 48%, with about one-third

Early results from a Phase 1/2 clinical trial suggest that ozekibart (INBRX-109), a targeted antibody, may offer a new option for patients with advanced colorectal cancer who have already received multiple treatments. When combined with standard chemotherapy (FOLFIRI), the drug showed stronger activity than typically seen in late-stage settings. Among 45 patients, about 20% experienced